<DOC>
	<DOC>NCT02662764</DOC>
	<brief_summary>Patients who meet all inclusion and exclusion criteria at screening and following surgery will receive the Zalviso System™ and evaluate its usability and functionality for up to 72 hours.</brief_summary>
	<brief_title>Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg</brief_title>
	<detailed_description>Approximately 315 adult postoperative in-patients who are expected to require opioid analgesia for at least 24 hours, and up to 72 hours, after surgery will be enrolled. Patients will use the Zalviso™ (sufentanil sublingual tablet system) 15 mcg in order to self-administer a tablet of study drug as needed for pain. The System will be evaluated for usability and functionality.</detailed_description>
	<mesh_term>Acute Pain</mesh_term>
	<mesh_term>Sufentanil</mesh_term>
	<criteria>1. Male or female patients who are 18 years of age or older. 2. Patients who are scheduled to undergo surgery under general or spinal anesthesia that does not include intrathecal opioids during the operation. 3. Patients classified as American Society of Anesthesiologists (ASA) class I III (Appendix I). 4. Female patients of childbearing potential must be using an effective method of birth control at the time of screening visit and for 30 days following the end of the study period. Acceptable methods of birth control include oral or transdermal contraceptives, condom, spermicidal foam, intrauterine device (IUD), progestin implant or injection, abstinence, vaginal ring, or sterilization of partner. The reason for nonchild bearing potential, such as bilateral tubal ligation, bilateral oophorectomy, hysterectomy, or postmenopausal for &gt; 1 year, must be specified. Patients using hormonal forms of contraception must also be willing to use a barrier method of contraception from screening through 30 days following the study period. 5. Postsurgical patients who have been admitted to the PACU, and are expected to have acute pain requiring opioids for 24 72 hours after surgery. 1. Patients who have taken an opioid for more than 30 consecutive days, at a daily dose of 15 mg or more of morphine (or equivalent), within the past 3 months prior to surgery (e.g. more than 3 doses per day of Vicodin®, Norco®, Lortab® with 5 mg hydrocodone per tablet). 2. Patients who are currently taking monoamine oxidase inhibitors (MAOIs) or have taken MAOIs within 14 days of the first dose of study drug. 3. Patients with current sleep apnea that has been documented by a sleep laboratory study or are on home continuous positive airway pressure (CPAP). 4. Patients with an allergy or hypersensitivity to opioids. 5. Patients who are currently taking monoamine oxidase inhibitors (MAOIs) or have taken MAOIs within 14 days of the first dose of study drug. 6. Patients with current sleep apnea that has been documented by a sleep laboratory study or are on home continuous positive airway pressure (CPAP). 7. Patients who are receiving oxygen therapy at the time of screening.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>